Clinical Trials on Influenza Type B

Total 60444 results

Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
Novartis Vaccines

Completed

Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children

Haemophilus Influenzae Type B Infection

Korea, Republic of
Johns Hopkins Bloomberg School of Public Health
Merck Sharp & Dohme LLC

Completed

Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)

Haemophilus Influenzae Type B Infection

United States
Beijing Minhai Biotechnology Co., Ltd

Unknown

Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried

Haemophilus Influenzae Type b Infections

China
GlaxoSmithKline

Completed

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b | Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine

Poland, United Kingdom
GlaxoSmithKline

Completed

3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

Belgium, Germany
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
Centers for Disease Control and Prevention
National Institute of Allergy and Infectious Diseases (NIAID); Alaska Native... and other collaborators

Completed

Study to Eliminate Hib Carriage in Rural Alaska Native Villages

Haemophilus Influenzae Type B | Carrier State

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Novartis Vaccines

Completed

Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
Novartis Vaccines

Completed

Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b

Haemophilus Influenzae Type b

China
Merck Sharp & Dohme LLC

Completed

Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Hepatitis B | Haemophilus Influenzae Type B
LG Life Sciences

Completed

Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

Infectious Disease by Haemophilus Influenzae Type b

Korea, Republic of
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
LG Chem

Unknown

A Phase IV Study to Assess the Safety of EupentaTM Inj

Hepatitis B | Pertussis | Tetanus | Diphtheria | Haemophilus Influenzae Type B Infection
Sanwa BioTech Limited
Chinese University of Hong Kong; Prince of Wales Hospital, Shatin, Hong Kong

Not yet recruiting

Influenza A+B Test Kit Performance Study

Influenza Type B | Influenza Type A

Hong Kong
SAb Biotherapeutics, Inc.

Active, not recruiting

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Influenza | Influenza Type B | Influenza Type A

United States
Novartis Vaccines

Completed

Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China

Haemophilus Influenzae Type b (Hib) Infection

China
Public Health England

Completed

The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine

Haemophilus Influenzae Type b
St. Jude Children's Research Hospital
National Institute of Allergy and Infectious Diseases (NIAID); The University...

Completed

Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China

Influenza Type B | Influenza Type A

China
GlaxoSmithKline

Completed

Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine

Haemophilus Influenzae Type b Disease

China
GlaxoSmithKline

Completed

Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Vietnam
Vanderbilt University Medical Center
Human Vaccines Project

Completed

Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults (KIRV)

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1

United States
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
GlaxoSmithKline

Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain, Germany, Poland
GlaxoSmithKline

Completed

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
GlaxoSmithKline

Completed

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
GlaxoSmithKline

Completed

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Finland, Italy
GlaxoSmithKline

Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Poland, United Kingdom
GlaxoSmithKline

Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

Neisseria Meningitidis | Haemophilus Influenzae Type b

Spain
Novartis Vaccines

Completed

Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China

Haemophilus Influenzae Type b (Hib) Infection

China
GlaxoSmithKline

Completed

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand
GlaxoSmithKline

Completed

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

Hepatitis B | Tetanus | Diphtheria | Haemophilus Influenzae Type b | Whole Cell Pertussis | Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin

Thailand, Philippines
Takeda

Completed

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Healthy Volunteers | Haemophilus Influenzae Type b, Prevention

Japan
GlaxoSmithKline

Completed

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Haemophilus Influenzae Type b

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Poland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

India
LG Chem

Not yet recruiting

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type B Infection
Sanofi Pasteur, a Sanofi Company

Completed

Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type B Infection

Mexico
NPO Petrovax

Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

Vaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza Epidemic

Russian Federation
GlaxoSmithKline

Completed

Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Sweden, Norway
Novartis Vaccines

Completed

Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

Haemophilus Influenzae Type b (Hib) Infection

China
Novartis Vaccines

Completed

Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children

Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

China

Clinical Trials on Influenza Type B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations